Mitapivat
FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia
Clinical News
Giugno 11, 2020
FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia
Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of…